Brought to you by 
Pfizer, University College London ally in stem cell therapies
30 Apr 2009
Executive Summary
Just months after a ban was lifted on US government funding for embryonic stem cell research, Pfizer's five-month-old regenerative medicine unit and University College London's Institute of Ophthalmology have teamed up to develop stem cell therapies for eye diseases including wet and dry age-related macular degeneration (AMD).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer, University College London ally in stem cell therapies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice